



Pharmacy Utilization Management Programs and Changes for Minnesota Health Care Programs Effective September 1st, 2009

- Step Therapy for ARB/ARB Combination Products
 - Step Therapy will require use of ACE Inhibitor prior to use of Diovan, Diovan HCT, Cozaar, Hyzaar.
- Step Therapy for HMGs
 - Step Therapy will require use of generic HMG prior to use of Lipitor, Vytarin and Altoprev.
- Step Therapy for Zetia
 - Step Therapy will require use of an HMG prior to the use of Zetia.
- Step Therapy for Elidel/Protopic
 - Step Therapy will require use of generic topical corticosteroid prior to use of Elidel or Protopic.
- Step Therapy TZDs and DPP-4
 - Step Therapy will require use of metformin or sulfonylurea prior to the use of Actos, Actoplusmet, Avandia, Avandryl, Avandamet, Januvia, and Janumet
- Step Therapy for Celebrex
 - Current program that requires PA for Celebrex will change to Step Therapy. This program will require use of 2 generics prior to the use of Celebrex
- Formulary Changes
 - Avalida, Avapro, Atacand, Atacand HCT, Aciphex, and Zegerid removed from the formulary. Current utilizers of the above drugs will be allowed to continue therapy without prior authorization through 12/31/2009.

Affected UCare Products:

- Prepaid Medical Assistance Program (PMAP)
- Prepaid General Assistance Medical Care (PGAMC)
- MinnesotaCare
- Minnesota Senior Health Options (MSHO)*
- Minnesota Disability Health Options (MnDHO)*
- *UCare Connect**

* These programs are not applicable to members with Medicare Part D coverage.